The Effects of Supplemental Fish Oil on Blood Pressure and Morning Cortisol in Normotensive Adults: A Pilot Study

Purpose: To determine the effects of 6wk of supplementation with fish oil (FO) on blood pressure and the morning salivary cortisol concentration in normotensive adults. Methods: Testing was performed following an overnight fast. Subjects (n=40; 35+/-13y, mean+/-SD) rested supine for 40 min, at which time blood pressure and heart rate were measured. Saliva was collected and analyzed for cortisol. Subjects were then randomly assigned to either: 4g/d of Safflower Oil (SO); pr 4g/d of FO supplying 1,600mg/d eicosapentaenoic acid and 800mg/d docosahexaenoic acid. Testing was repeated following 6wk treatment. Results: Compared to SO, there was a significant decrease in systolic blood pressure with FO (SO= 1.3+/-5.8 mmHg; FO= -6.8+/-10.2 mmHg; p=0.004), a significant reduction in pulse pressure with FO (SO= 0.2+/-7.8 mmHg; FO= -6.4+/-8.8 mmHg; p=0.02), and a tendency for a decrease in mean arterial pressure (SO= 1.2+/-5.3 mmHg; FO= -2.5+/-7.3 mmHg; p=0.08). There was a tendency for salivary cortisol to decrease with FO (SO= 0.005+/-0.129 µg/dL; FO= -0.068+/-0.148 µg/dL; p=0.072), however, this change was not significant;y correlated with the change in systolic blood pressure (r=0.021, p=0.929). Conclusion: 6wk of supplementation with FO significantly decreases systolic blood pressure in normotensive adults and this change was not significantly correlated with a reduction in salivary cortisol

Supplemental fish oil decreases urinary excretion of a marker of bone resorption in healthy adults

Background: Incorporation of fish oil (FO) into the diet of rodents has been shown to result in positive changes in bone health. Currently it is poorly understood if FO has the same effects on bone health in humans. The purpose of this study was to determine the effects of supplemental FO on levels of urinary N-terminal cross-linked telopeptide (NTx), which is a marker of bone breakdown, and how this is related to the morning levels of salivary cortisol and urinary excretion of interleukin 6 (IL-6). Methods: A total of twenty-eight females and twelve males(35 ± 13yrs; 69.1 ± 14.1kg; 29.4 ± 9.2% body fat; mean ± SD) participated in this study. All testing was conducted in the morning following an overnight fast. Baseline measurements of salivary cortisol were collected via passive drool and baseline measurements of urinary NTxand IL- 6 were collected from the second void of the day and corrected for creatinine excretion. After baseline testing, subjects were assigned randomly in a double blind manner to one of two groups: 4 g/d of Safflower Oil (SO) or 4 g/d of FO supplying 1,600 mg/d eicosapentaenoic acid (EPA) and 800 mg/d docosahexaenoic acid (DHA). All tests were repeated following 6wk of treatment. A treatment by time, repeated measures ANOVA was used to evaluate differences between groups over time, and a standard Pearson’s r was used to evaluate correlations. Additionally, within group pre-post differences were evaluated using a repeated measures t-test. For all analysis, the alpha level was set at p\u3c0.05. Results: Compared to the SO group, there was a significant decrease in urinary creatinine corrected NTx excretion following FO treatment (SO = 17.5 ± 42.9 BCE/mM; FO = -11.3 ± 27.7 BCE/mM; p=0.02). There was also a tendency for urinary creatinine corrected IL-6 excretion (SO = -0.08 ± 1.18pg/mg; FO = -1.8 ± 3.8 pg/mg; p=0.08), and salivary cortisol (SO = 0.029±0.283 μg/dL; FO = -0.069 ± 0.144 μg/dL; p=0.13) to decrease following FO treatment.When analyzed independently, however, there was a significant pre-post reduction for salivary cortisol in the FO group (p=0.04), with no change in the SO group (p=0.68), as well as a significant reduction pre-post for urinary IL-6 in the FO group (p=0.05), with no change in the SO group (p=0.78). However, the change in urinary NTx concentrationwas not related to the change insalivary cortisol concentration( r=-0.017, p=0.9), or the change in urinary IL-6 concentration (r=-0.323, p=0.26). Conclusions: Six weeks of supplementation with FO in adults significantly decreased urinary NTx excretion, but this change was not related to changes in cortisol or IL-6

Recovery from a cycling time trial is enhanced with carbohydrate-protein supplementation vs. isoenergetic carbohydrate supplementation

Background: In this study we assessed whether a liquid carbohydrate-protein (C+P) supplement (0.8 g/kg C; 0.4 g/kg P) ingested early during recovery from a cycling time trial could enhance a subsequent 60 min effort on the same day vs. an isoenergetic liquid carbohydrate (CHO) supplement (1.2 g/kg). Methods: Two hours after a standardized breakfast, 15 trained male cyclists completed a time trial in which they cycled as far as they could in 60 min (AMex) using a Computrainer indoor trainer. Following AMex, subjects ingested either C+P, or CHO at 10, 60 and 120 min, followed by a standardized meal at 4 h post exercise. At 6 h post AMex subjects repeated the time trial (PMex). Results: There was a significant reduction in performance for both groups in PMex versus AMex. However, performance and power decreases between PMex and AMex were significantly greater (p ≤ 0.05) with CHO (-1.05 ± 0.44 km and -16.50 ± 6.74 W) vs C+P (-0.30 ± 0.50 km and -3.86 ± 6.47 W). Fat oxidation estimated from RER values was significantly greater (p ≤ 0.05) in the C+P vs CHO during the PMex, despite a higher average workload in the C+P group. Conclusion: Under these experimental conditions, liquid C+P ingestion immediately after exercise increases fat oxidation, increases recovery, and improves subsequent same day, 60 min efforts relative to isoenergetic CHO ingestion

The effect of caffeine ingestion on perception of muscle pain during a sustained submaximal isometric contraction of the quadriceps

Background: The purpose of this study was to determine the effects of an acute dose of 5 mg/kg of caffeine on perceived pain of the quadriceps during a sustained submaximal isometric contraction. Methods: A total of 15 low caffeine consuming college aged women (20.5 ± 1.4 y, 66.0 ± 9.0 kg; mean ± SD) participated in this study. 2–7 d after a familiarization trial subjects ingested, in a double blind random crossover manner, either 5 mg/kg caffeine (Caf) or a placebo (P), 1 h prior to performing a 2 min isometric leg extension at 45% of peak torque using visual cues to maintain force production. Every 15 s subjects rated their level of pain using the Borg CR10 pain scale. Subjects returned to the lab 2–7 d later to repeat the testing with the other condition. Data were analyzed using a repeated measures ANOVA with a Tukey\u27s HSD post hoc. Results: Caffeine ingestion resulted in a lower pain score at all time points during the 2 min isometric contraction. This difference approached significance at 90 s (Caf = 3.2 ± 1.4, P = 4.1 ± 1.4; p \u3c 0.10), and became significantly different at 105 s (Caf = 3.8 ± 1.2, P = 4.9 ± 1.5; p \u3c 0.05) and at 120 s (Caf = 4.4 ± 1.5, P = 5.4 ± 1.5; p \u3c 0.05). Conclusion: Acute caffeine ingestion attenuates perception of muscle pain in the quadriceps during a sustained submaximal isometric contraction. This effect become

Effects of supplemental fish oil on resting metabolic rate, body composition, and salivary cortisol in healthy adults

<p>Abstract</p> <p>Background</p> <p>To determine the effects of supplemental fish oil (FO) on resting metabolic rate (RMR), body composition, and cortisol production in healthy adults.</p> <p>Methods</p> <p>A total of 44 men and women (34 ± 13y, mean+SD) participated in the study. All testing was performed first thing in the morning following an overnight fast. Baseline measurements of RMR were measured using indirect calorimetry using a facemask, and body composition was measured using air displacement plethysmography. Saliva was collected via passive drool and analyzed for cortisol concentration using ELISA. Following baseline testing, subjects were randomly assigned in a double blind manner to one of two groups: 4 g/d of Safflower Oil (SO); or 4 g/d of FO supplying 1,600 mg/d eicosapentaenoic acid (EPA) and 800 mg/d docosahexaenoic acid (DHA). All tests were repeated following 6 wk of treatment. Pre to post differences were analyzed using a treatment X time repeated measures ANOVA, and correlations were analyzed using Pearson's r.</p> <p>Results</p> <p>Compared to the SO group, there was a significant increase in fat free mass following treatment with FO (FO = +0.5 ± 0.5 kg, SO = -0.1 ± 1.2 kg, p = 0.03), a significant reduction in fat mass (FO = -0.5 ± 1.3 kg, SO = +0.2 ± 1.2 kg, p = 0.04), and a tendency for a decrease in body fat percentage (FO = -0.4 ± 1.3% body fat, SO = +0. 3 ± 1.5% body fat, p = 0.08). No significant differences were observed for body mass (FO = 0.0 ± 0.9 kg, SO = +0.2 ± 0.8 kg), RMR (FO = +17 ± 260 kcal, SO = -62 ± 184 kcal) or respiratory exchange ratio (FO = -0.02 ± 0.09, SO = +0.02 ± 0.05). There was a tendency for salivary cortisol to decrease in the FO group (FO = -0.064 ± 0.142 μg/dL, SO = +0.016 ± 0.272 μg/dL, p = 0.11). There was a significant correlation in the FO group between change in cortisol and change in fat free mass (r = -0.504, p = 0.02) and fat mass (r = 0.661, p = 0.001).</p> <p>Conclusion</p> <p>6 wk of supplementation with FO significantly increased lean mass and decreased fat mass. These changes were significantly correlated with a reduction in salivary cortisol following FO treatment.</p

Differential diagnosis of illness in travelers arriving from sierra Leone, Liberia, or guinea: A cross-sectional study from the Geosentinel surveillance network

Background: The largest-ever outbreak of Ebola virus disease (EVD), ongoing in West Africa since late 2013, has led to export of cases to Europe and North America. Clinicians encountering ill travelers arriving from countries with widespread Ebola virus transmission must be aware of alternate diagnoses associated with fever and other nonspecific symptoms. Objective: To define the spectrum of illness observed in persons returning from areas of West Africa where EVD transmission has been widespread. Design: Descriptive, using GeoSentinel records. Setting: 57 travel or tropical medicine clinics in 25 countries. Patients: 805 ill returned travelers and new mmigrants from Sierra Leone, Liberia, or Guinea seen between September 2009 and August 2014. Measurements: Frequencies of demographic and travelrelated characteristics and illnesses reported. Results: The most common specific diagnosis among 770 nonimmigrant travelers was malaria (n = 310 [40.3%]), with Plasmodium falciparum or severe malaria in 267 (86%) and non–P. falciparum malaria in 43 (14%). Acute diarrhea was the second most common diagnosis among nonimmigrant travelers (n= 95 [12.3%]). Such common diagnoses as upper respiratory tract infection, urinary tract infection, and influenza-like illness occurred in only 26, 9, and 7 returning travelers, respectively. Few instances of typhoid fever (n = 8), acute HIV infection (n = 5), and dengue (n = 2) were encountered. Limitation: Surveillance data collected by specialist clinics may not be representative of all ill returned travelers. Conclusion: Although EVD may currently drive clinical evaluation of ill travelers arriving from Sierra Leone, Liberia, and Guinea, clinicians must be aware of other more common, potentially fatal diseases. Malaria remains a common diagnosis among travelers seen at GeoSentinel sites. Prompt exclusion of malaria and other life-threatening conditions is critical to limiting morbidity and mortality

A nomenclature for restriction enzymes, DNA methyltransferases, homing endonucleases and their genes

A nomenclature is described for restriction endonucleases, DNA methyltransferases, homing endonucleases and related genes and gene products. It provides explicit categories for the many different Type II enzymes now identified and provides a system for naming the putative genes found by sequence analysis of microbial genome

Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context

Long noncoding RNAs (lncRNAs) are commonly dys-regulated in tumors, but only a handful are known toplay pathophysiological roles in cancer. We inferredlncRNAs that dysregulate cancer pathways, onco-genes, and tumor suppressors (cancer genes) bymodeling their effects on the activity of transcriptionfactors, RNA-binding proteins, and microRNAs in5,185 TCGA tumors and 1,019 ENCODE assays.Our predictions included hundreds of candidateonco- and tumor-suppressor lncRNAs (cancerlncRNAs) whose somatic alterations account for thedysregulation of dozens of cancer genes and path-ways in each of 14 tumor contexts. To demonstrateproof of concept, we showed that perturbations tar-geting OIP5-AS1 (an inferred tumor suppressor) andTUG1 and WT1-AS (inferred onco-lncRNAs) dysre-gulated cancer genes and altered proliferation ofbreast and gynecologic cancer cells. Our analysis in-dicates that, although most lncRNAs are dysregu-lated in a tumor-specific manner, some, includingOIP5-AS1, TUG1, NEAT1, MEG3, and TSIX, synergis-tically dysregulate cancer pathways in multiple tumorcontexts

Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas

Although theMYConcogene has been implicated incancer, a systematic assessment of alterations ofMYC, related transcription factors, and co-regulatoryproteins, forming the proximal MYC network (PMN),across human cancers is lacking. Using computa-tional approaches, we define genomic and proteo-mic features associated with MYC and the PMNacross the 33 cancers of The Cancer Genome Atlas.Pan-cancer, 28% of all samples had at least one ofthe MYC paralogs amplified. In contrast, the MYCantagonists MGA and MNT were the most frequentlymutated or deleted members, proposing a roleas tumor suppressors.MYCalterations were mutu-ally exclusive withPIK3CA,PTEN,APC,orBRAFalterations, suggesting that MYC is a distinct onco-genic driver. Expression analysis revealed MYC-associated pathways in tumor subtypes, such asimmune response and growth factor signaling; chro-matin, translation, and DNA replication/repair wereconserved pan-cancer. This analysis reveals insightsinto MYC biology and is a reference for biomarkersand therapeutics for cancers with alterations ofMYC or the PMN

Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas

This integrated, multiplatform PanCancer Atlas study co-mapped and identified distinguishing molecular features of squamous cell carcinomas (SCCs) from five sites associated with smokin